Are We Measuring What Really Counts?

被引:2
作者
Thoma, Achilleas [1 ]
Hassan, Yusuf [1 ]
Santos, Jenny [1 ]
机构
[1] McMaster Univ, Hamilton, ON, Canada
关键词
PATIENT-REPORTED OUTCOMES; S-APR ARTISS; HYALURONIC-ACID; AUGMENTATION MAMMAPLASTY; SAFETY; EFFICACY; SURGERY; BREAST; MULTICENTER; LIPOSUCTION;
D O I
10.1093/asj/sjz083
中图分类号
R61 [外科手术学];
学科分类号
摘要
Most published clinical research is faulty because of many reasons, one being faulty design. A remedy to this problem is the correct utilization of the PICOT (population, intervention, comparative intervention, outcome and time horizon) format in the design of a clinical research question. One element of the PICOT format, outcome, has not been assessed adequately in aesthetic surgery. In this review, we found that in the last decade of all randomized controlled trials and comparative studies published in Aesthetic Surgery Journal, only about half specified a primary outcome. Regrettably, only 40% reported both a primary outcome and justification for choosing this outcome. This poses a credibility issue with the conclusions of the majority of published studies. There is an urgent need to develop critical outcome sets for aesthetic procedures to be utilized by future investigators. With such a critical outcome set, we will be able to pool the results of multiple studies on the same subject and reach conclusive results.
引用
收藏
页码:777 / 785
页数:9
相关论文
共 50 条
  • [41] What do we know? What do we need to know?
    Henzlova, Milena J.
    Duvall, W. Lane
    JOURNAL OF NUCLEAR CARDIOLOGY, 2017, 24 (01) : 252 - 254
  • [42] Sepsis in veterinary patients: what do we know and where can we go?
    Otto, Cynthia M.
    JOURNAL OF VETERINARY EMERGENCY AND CRITICAL CARE, 2007, 17 (04) : 329 - 332
  • [43] Gadolinium in pediatric cardiovascular magnetic resonance: what we know and how we practice
    Meng, Howard
    Grosse-Wortmann, Lars
    JOURNAL OF CARDIOVASCULAR MAGNETIC RESONANCE, 2012, 14
  • [44] Omalizumab for severe allergic asthma in clinical trials and real-life studies: What we know and what we should address
    Caminati, Marco
    Senna, Gianenrico
    Guerriero, Massimo
    Darna, Anna Rita
    Chieco-Bianchi, Fulvia
    Stefanizzi, Giorgia
    Montagni, Marcello
    Ridolo, Erminia
    PULMONARY PHARMACOLOGY & THERAPEUTICS, 2015, 31 : 28 - 35
  • [45] Augmented Renal Clearance: What Have We Known and What Will We Do?
    Luo, Yifan
    Wang, Yidan
    Ma, Yue
    Wang, Puxiu
    Zhong, Jian
    Chu, Yang
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [48] Epoetin Biosimilars in the Treatment of Renal Anemia: What Have We Learned from a Decade of European Experience?
    Goldsmith, David
    Dellanna, Frank
    Schiestl, Martin
    Krendyukov, Andriy
    Combe, Christian
    CLINICAL DRUG INVESTIGATION, 2018, 38 (06) : 481 - 490
  • [49] Perihilar-cholangiocarcinoma: what really matters?
    Di Benedetto, Fabrizio
    Magistri, Paolo
    Di Sandro, Stefano
    HEPATOBILIARY SURGERY AND NUTRITION, 2022, 11 (04) : 616 - 619
  • [50] What Do We Really Know About the Safety of Tai Chi?: A Systematic Review of Adverse Event Reports in Randomized Trials
    Wayne, Peter M.
    Berkowitz, Danielle L.
    Litrownik, Daniel. E.
    Buring, Julie E.
    Yeh, Gloria Y.
    ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION, 2014, 95 (12): : 2470 - 2483